Chromosomal translocation products engender new intracellular therapeutic technologies.
Chromosomal translocations occur in leukemias, lymphomas, sarcomas and some epithelial tumors and some generate unique fusion proteins. These translocation products may provide tumor-specific targets for the development of new therapeutic strategies tailored to a malignant cell.
主要な著者: | Rabbitts, T, Stocks, MR |
---|---|
フォーマット: | Journal article |
言語: | English |
出版事項: |
2003
|
類似資料
-
Chromosomal translocation master genes, mouse models and experimental therapeutics.
著者:: Rabbitts, T
出版事項: (2001) -
Intracellular antibodies and cancer: new technologies offer therapeutic opportunities.
著者:: Pérez-Martínez, D, 等
出版事項: (2010) -
Mouse models of human chromosomal translocations and approaches to cancer therapy.
著者:: Rabbitts, T, 等
出版事項: (2001) -
The promiscuous MLL gene links chromosomal translocations to cellular differentiation and tumour tropism.
著者:: Collins, E, 等
出版事項: (2002) -
The role of LMO2 in development and in T cell leukemia after chromosomal translocation or retroviral insertion.
著者:: Nam, C, 等
出版事項: (2006)